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Abstract
Objectives—The optimal management of locally advanced and metastatic pulmonary carcinoid 
tumors remains to be determined.
Materials and methods—A retrospective review was conducted on patients with typical and 
atypical pulmonary carcinoid tumors treated at our institutions between 1990 and 2012.
Results—300 patients were identified with pulmonary carcinoid, (80 patients with atypical 
carcinoid), of whom 29 presented with metastatic disease (16 atypical). Of evaluable patients, 26 
(41%) with stages I–III atypical carcinoid tumors recurred at a median time of 3.7 years (range, 
0.4–32), compared to 3 (1%) patients with typical carcinoid (range, 8–12.3). 39 patients were 
treated with chemotherapy, including 30 patients with metastatic disease (27 atypical), and 7 
patients were treated with adjuvant platinum–etoposide chemoradiation (6 atypical, 1 typical, 6 
stage IIIA, 1 stage IIB). At a median follow-up of 2 years there were 2 recurrences in the 7 
patients receiving adjuvant treatment. Median survival after diagnosis of metastatic disease for 
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patients with atypical pulmonary carcinoid was 3.3 years with a 5-year survival of 24%. Treatment 
regimens showing efficacy in pulmonary carcinoid include 15 patients treated with octreotide-
based therapies (10% response rate (RR), 70% disease control rate (DCR), 15 month median 
progression-free survival (PFS)), 13 patients treated with etoposide + platinum (23% RR, 69% 
DCR, 7 month median PFS), and 14 patients treated with temozolomide-based therapies (14% RR, 
57% DCR, 10 month median PFS). 8 of 10 patients with octreotide-avid disease treated with an 
octreotide-based regimen experienced disease control (1 partial response, 7 stable disease) for a 
median of 18 months (range 6–72 months).
Conclusions—These results support our previous finding that a subset of pulmonary carcinoid 
tumors are responsive to chemotherapy.
1. Introduction
Patients with pulmonary carcinoid tumors comprise approximately 2% of all primary lung 
cancers [1], and the relative rarity of these tumors complicates efforts to effectively plan the 
therapy of patients with locally advanced or metastatic cancer. Pulmonary carcinoid tumors 
are defined by their typically bland cytomorphology and neuroendocrine features on 
histologic examination, and immunohistochemical staining for chromogranin, neural cell 
adhesion molecule (CD56), or synaptophysin [2]. A spectrum of pulmonary neuroendocrine 
tumors is thought to exist, with carcinoid tumorlets and diffuse idiopathic pulmonary 
neuroendocrine cell hyperplasia (DIPNECH) representing less aggressive forms of the 
neuroendocrine spectrum, and small cell lung cancer the most malignant [2]. Typical 
carcinoid tumors behave in a more indolent fashion compared to atypical carcinoid tumors, 
which have a greater propensity for dissemination at the time of presentation and the 
subsequent development of metastasis. The pathologic criteria that distinguishes typical 
from atypical carcinoid tumors were proposed by Travis et al., in 1998, and has been widely 
adopted [3]. Typical carcinoids are distinguished from carcinoid tumorlets by a size larger 
than 0.5 cm, and have a mitotic rate of <2 mitoses/10 high power field (HPF) with no 
necrosis [2]. Atypical carcinoids, in contrast, have a mitotic rate of 2–10 mitoses/10 HPF or 
the presence of necrosis.
Patients with typical carcinoids have an excellent prognosis, with 5- and 10-year survival 
rates of 85% reported [4]. Atypical carcinoids have a more aggressive course, with 5- and 
10-year survival rates in the range of 35–44%, due to a greater frequency of patients 
presenting with advanced stage and more frequent recurrence [4]. While metastatic disease 
is rarely reported for typical carcinoid tumors, atypical carcinoid tumors do metastasize in 
approximately 30–40% of reported cases, with the liver, bone, and brain being the most 
common sites [4]. Treatment of patients with typical carcinoids has centered on resection, 
and the vast majority of patients in case-series remain recurrence free for years, and even 
decades, with little information on systemic treatment [5], [6] and [7].
The more aggressive nature of atypical carcinoid tumors compared to typical carcinoid 
tumors prompted investigators to administer adjuvant chemotherapy for high-risk disease 
(i.e. stage IIB/IIIA) based on data showing a response rate of 20% to any chemotherapy [8], 
although this approach has been questioned by others who feel the role of systemic 
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treatment is limited [9]. Regimens showing antitumor activity against pulmonary carcinoid 
tumors include octreotide [10], doxorubicin/capecitabine [11], everolimus + cisplatin [12], 
everolimus + octreotide [13], and etoposide + cisplatin [8]. The efficacy of adjuvant 
treatment for stages II and III resected typical and atypical carcinoid tumors is extrapolated 
from these response rates in metastatic disease, and the efficacy of adjuvant chemotherapy 
in resected stage II and III non-small cell lung cancer trials [14], [15] and [16]. While 
patients with pulmonary carcinoid tumors have been included in large-scale studies of 
neuroendocrine tumors [17], very little data exist on the role of chemotherapy in locally 
advanced typical or atypical metastatic pulmonary carcinoid tumors.
To further define the role of chemotherapy and adjuvant treatment of pulmonary carcinoid 
tumors, this retrospective study of patients with atypical and typical carcinoid tumors treated 
at our institutions between 1990 and 2012 was undertaken. This study updates our 2004 
effort which demonstrated that pulmonary carcinoid tumors can respond to chemotherapy 
[8].
2. Materials and methods
This study was approved by the Dana-Farber/Harvard Cancer Center institutional review 
board. Patients with pulmonary carcinoid tumors were identified in the Brigham and 
Women's Hospital pathology database, and the Tumor Registry and radiation oncology 
databases of the Dana-Farber Cancer Institute using the search terms: pulmonary carcinoid, 
bronchial carcinoid, and lung carcinoid. Approximately 800 records from 1990 to 2012 were 
reviewed, and those that included (1) a diagnosis of typical or atypical pulmonary carcinoid, 
and (2) treatment with chemotherapy or surgery, are presented. Records were crosslinked to 
patients reported in our previous study [8], under which tumor samples that predated the 
1999 update in the WHO criteria were re-examined. Patients with pathology reports that 
failed to mention the number of mitoses and/or the presence/absence of necrosis underwent 
further pathologic review by a pulmonary pathologist (LS) to classify the tumor as typical or 
atypical carcinoid. Using these criteria, 300 patients are included in our study.
Data from the medical records was reviewed and entered into a computer database by a 
single investigator (CRC), including gender, age, smoking status, presenting symptoms, date 
of diagnosis, stage, site of presentation, date of documented metastatic disease, treatment, 
response to treatment, time to progression, last time of follow-up, and date and cause of 
death. The duration of survival for early stage disease was determined from time of first 
diagnosis to the date of last follow-up or death as ascertained from the medical record or the 
Social Security Death Index. The duration of survival for patients with metastatic disease 
was determined from date of documentation of metastatic disease to date of last follow-up or 
death as ascertained from the medical record or the Social Security Death Index. The results 
of imaging studies (i.e. PET CT and/or octreotide scans) and specialized lab studies (i.e. 
serum chromogranin and urinary 5-HIAA) were included if studied and reported in the 
medical record. Disease control is defined as patients who achieve a complete/partial 
response or stable disease (minimum of 2 months) with treatment. The imaging studies were 
reviewed by a board-certified thoracic radiologist (MN) to determine response by Response 
Evaluation Criteria in Solid Tumors (RECIST) criteria if pretreatment and post-treatment 
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scans were available. Progression for patients in whom pre/post-treatment scans were 
unavailable was determined based on notes in the medical record. Sites of metastatic disease 
were noted on scans after disease progression as documented in radiology reports.
3. Results
3.1. Patient characteristics
The characteristics of patients represented in this study are presented in Table 1. Patients 
with pulmonary carcinoid presented at a median age of ~60 years and were predominantly 
women. Of patients with atypical or typical carcinoid, 48% and 41% had a smoking history, 
respectively. The most common reason for diagnosis was an unusual finding on chest 
radiograph or CT performed for other reasons in a patient who did not have any pulmonary 
symptoms directly related to the tumor. The next most common symptomatic presentation 
for both typical and atypical carcinoids were cough and recurrent pneumonia. Many of the 
presenting symptoms were non-specific, and included chest/back/shoulder pain or dyspnea. 
Symptoms of carcinoid syndrome, which are commonly seen with GI carcinoids, such as 
flushing were observed in 4 patients with atypical pulmonary carcinoid (5%) and in no 
patients with typical pulmonary carcinoid. Pulmonary carcinoid has been associated with 
Cushing syndrome and multiple endocrine neoplasia [18] and [19]. Typical carcinoid was 
diagnosed during workup of these diseases in 7 patients.
3.2. Diagnostic evaluation
Carcinoid tumors can produce neuroendocrine secretory proteins such as chromogranin and 
metabolites such as 5-hydroxyindoleacetic acid (5-HIAA) that can enter the circulation and 
produce symptoms such as flushing, palpitations, and diarrhea. When tested, the 
chromogranin level was elevated in 20 of 33 patients (61%) with atypical carcinoid, 
compared to 11 of 32 patients (34%) with typical carcinoid. The urinary 5-HIAA level was 
elevated above the limit of normal (>8 mg/24 h) in 15 of 33 patients with atypical carcinoid 
(46%), and in none of the patients with typical carcinoid. Of patients with metastatic 
atypical carcinoid, the chromogranin level was elevated in 14 of 19 (74%) and the urinary 5-
HIAA level was elevated in 12 of 19 (63%). Significantly, of the 4 patients with atypical 
carcinoid who presented with flushing, 3 had urinary 5-HIAA tested, and the value was 
elevated in all 3 patients (9, 9.5, 12 mg/24 h). Of the patients who presented with flushing, 3 
had metastatic atypical carcinoid, and 2 died of this disease.
Of patients with atypical carcinoid tumors, 15 had the proliferation index measured by Ki67 
or MIB-1 staining. The median proliferative index was 10% (range 3–35%). There were 
insufficient data to correlate the proliferative index with the presence/absence of necrosis, 
the mitoses per HPF, or disease course.
Considerable efforts are devoted to the imaging of pulmonary carcinoid tumors using PET-
CT and labeling with a variety of ligands [20] and [21]. To further define the role of PET-
CT and octreotide scintigraphy in the evaluation of pulmonary carcinoid tumors the imaging 
findings were reviewed when available for our patient cohorts. PET positive disease was 
defined as radiotracer uptake greater than background values, and this was seen in 28 of 30 
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patients with atypical carcinoid (93%) and in 40 of 58 (69%) of patients with typical 
carcinoid. All 17 patients with metastatic atypical carcinoid who had an FDG-avid primary 
lung lesion had FDG-avid metastatic lesions. Octreotide scans were positive in 9 of 13 
patients with atypical carcinoid (69%) and in 13 of 15 patients with typical carcinoid (87%). 
Of the three patients with atypical pulmonary carcinoid who had both a PET-CT and an 
octreotide scan, tumor was FDG and octreotide avid in two patients.
3.3. Disease course
Most patients with pulmonary carcinoid were diagnosed at an early stage of disease (IA or 
IB), while a metastatic presentation was over 3-fold more common for atypical disease (20% 
vs. 6%) than typical carcinoid. The anatomic distribution of primary tumors was similar 
between atypical and typical carcinoids. As previously demonstrated in multiple case series, 
the risk of recurrence was higher for resected atypical compared to typical carcinoids, with 
26 of 64 (41%) of resected atypical patients experiencing disease recurrence at a median 
time from surgery of 3.7 years (Fig. 1A, Table 2A). This was in contrast to 3 patients (1%) 
with resected typical carcinoid who experienced a recurrence at 8, 9, and 12 years. 5-year 
survival for atypical carcinoid from time of diagnosis was 95% for patients with stage I 
disease, 80% for patients with stage II disease, and 76% for patients with stage III disease 
(Fig. 1B).
Metastases were observed in both typical and atypical carcinoid tumors. In cases where 
typical carcinoid tumors were observed in both lungs, it is unclear whether this represents 
true metastasis, enlarging tumorlets, or a tendency to form multiple primary pulmonary 
carcinoid tumors. Sites of involvement for patients with typical carcinoid tumors included 
the liver (pathologically confirmed in 1 patient) and lytic bone lesions (2 patients). No 
patient with metastatic typical carcinoid died during the duration of their observation. In 
contrast, 34 patients with atypical carcinoid experienced metastasis most commonly to the 
liver in 27 patients (79%) followed by the bone in 18 patients (53%), brain in 6 patients 
(18%), soft tissue in 3 patients (9%), and adrenal/spleen in 2 patients each (6%) (Table 2B). 
Once metastatic disease developed in patients with atypical carcinoid, a median survival of 
3.3 years was observed (Fig. 2B).
3.4. Response to treatment
Thirty-nine patients were treated with 76 regimens, 35 of whom had atypical carcinoid 
(Table 3, Supplementary Table 1). Treatment regimens were grouped into 5 categories: 
etoposide-based (13 patients treated), temozolomide-based (14 patients), other cytotoxic 
treatments (8 patients), octreotide-based (15 patients), and clinical trials (7 patients). 
Treatment of atypical carcinoid with any cytotoxic regimen yielded a response in 7/37 
regimens (19%, 2 partial responses in 4 neoadjuvant cytotoxic regimens, and 1 complete 
response and 4 partial responses in 33 regimens used in metastatic disease), a median 
progression free survival of 7 months, and disease control with 24/37 regimens (65%). 
Etoposide-platinum regimens are used given the efficacy of this therapy in small cell lung 
cancer, and previous data showing some efficacy in pulmonary carcinoid tumors [8]. Three 
of 13 patients (23%) responded to an etoposide-platinum regimen, with a median PFS of 7 
months, and 9 of 13 (69%) patients achieved disease control. One patient with metastatic 
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atypical carcinoid experienced a complete response to carboplatin + etoposide. 
Temozolomide-based treatments resulted in a response in 2 of 14 patients (14%), with a 10 
month median PFS, and disease control in 8 of 14 patients (57%). Octreotide-based therapy 
resulted in a response in 2 of 15 patients treated with 20 regimens (10%), a median PFS of 
15 months, and disease control in 14 patients (70%). Octreotide-based scans were performed 
in 10 of the 15 patients treated with octreotide-based regimens, and in all cases the scan 
showed octreotide-avid disease. Of patients with octreotide-avid disease, 7 showed either a 
partial response (1 patient) or stable disease (6 patients) to an octreotide-based regimen, 
while 2 patients had progressive disease, and one patient who had stable disease with 
octreotide developed progressive disease by RECIST criteria on pasireotide.
Adjuvant treatment was pursued in 7 patients, 6 of whom had atypical carcinoid 
(Supplementary Table 2). At present, two patients developed metastatic recurrence at 2.1 
and 4.6 years, while the other 5 are free of recurrent carcinoid at a median follow-up of 14 
months (3–23 months). Neoadjuvant treatment was pursued in 4 patients with stage IIIA 
atypical carcinoid; all of these patients experienced recurrence and died of metastatic 
disease.
4. Discussion
This retrospective review was undertaken to further define the role of chemotherapy in the 
management of locally advanced or metastatic pulmonary carcinoid. Treatment with 
cytotoxic chemotherapy was associated with an 18% response rate in patients with atypical 
carcinoid, which is consistent with our previous finding in 2004 of a 22% response rate, also 
in patients with atypical carcinoid [8]. Only one patient with typical carcinoid was treated 
with any cytotoxic regimen (temozolomide) and achieved stable disease for 4 months. Three 
patients with typical carcinoid were treated with octreotide-based regimens and achieved 
stable disease for 11, 20, and 72 months.
Etoposide plus a platinum agent showed a response in 3 of 13 patients with atypical 
carcinoid (23%), with a complete response in one patient with metastatic disease. Given the 
activity of etoposide + platinum based regimens in the metastatic setting, and the high rate 
of recurrence for stage II and III disease (44% and 57%, respectively), this regimen has been 
used at times in combination with chest radiotherapy at our institution as an adjuvant 
treatment for patients with stage III disease. Two of seven patients treated with adjuvant 
chemo-radiotherapy developed metastatic disease, three patients with atypical disease 
remain recurrence-free after 17, 18, and 23 months of observation, and one developed an 
ALK mutant Ewing sarcoma at the completion of adjuvant treatment.
Temozolomide and octreotide-based regimens also showed antitumor activity. A response 
rate to temozolomide is noted in 2 patients (14%), a disease control rate in 8 patients (57%), 
and a median PFS of 10 months. This is similar to a recent retrospective report of 31 
patients, 14 of whom had typical pulmonary carcinoid, which noted a response rate in 3 of 
22 patients evaluable with RECIST (14%), stable disease in 11 patients (52%), a median 
PFS of 5.3 months, and a median overall survival of 23.2 months from the start of 
temozolomide treatment [22].
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We report two patients treated with everolimus and either pasireotide or sorafenib; both 
patients achieved stable disease for 24 and 12 months, respectively. The RADIANT-2 trial 
studied the use of everolimus + octreotide vs. octreotide alone in patients with unresectable 
or metastatic low to intermediate grade neuroendocrine tumors and a history of carcinoid 
symptoms [17]. A subset analysis of the 44 patients with pulmonary carcinoid (75% typical) 
showed treatment with everolimus + octreotide resulted in a trend toward prolonged 
progression-free survival (13.6 vs. 5.6 months, p = 0.23, HR = 0.72, 95% CI = 0.31–1.68) 
compared to octreotide alone [13]. Given the indolent nature of typical carcinoid and the fact 
that only 2–5% of patients with pulmonary carcinoid have carcinoid-type symptoms, it is 
unclear how these results apply to the patients reported in our study.
Octreotide has been used to treat metastatic atypical carcinoid tumors, and we observed a 
10% response rate, a 70% disease control rate, and a median PFS of 15 months in the 12 
patients treated. Of patients with resected pulmonary atypical carcinoid presenting with 
carcinoid syndrome due to recurrence in the liver, octreotide treatment resulted in resolution 
of carcinoid symptoms and normalization of urinary 5-HIAA levels in 5 of 5 patients [23]. 
Octreotide treatment was associated with a partial response in 2 of 5 patients, and a 
complete response in 1 of 5 patients [23]. Treatment with octreotide resulted in control of 
carcinoid symptoms and a partial tumor response, both of which were maintained for 9 years 
in a case report of a patient with extensive (>70%) hepatic involvement by a recurrent 
“classic” type pulmonary carcinoid 12 years after resection [24]. There is a case report of a 
woman with a resected atypical pulmonary carcinoid treated with 6 cycles of adjuvant 
carboplatin, etoposide, and epirubicin followed by 10 years of adjuvant octreotide with no 
evidence of recurrent disease [10].
Other regimens with reported efficacy in pulmonary carcinoid include liposomal 
doxorubicin + capecitabine (case report of a single patient with typical carcinoid and a 
partial response) [11], everolimus + cisplatin (of 3 patients with metastatic pulmonary 
carcinoid, partial response was seen in 2 patients with atypical disease and 1 patient had 
stable disease) [12], and navitoclax [25].
This study confirms the widely noted observation that typical carcinoids behave in a much 
more indolent fashion than atypical carcinoid tumors. Metastatic disease for atypical 
carcinoid tumors was noted primarily in the bone [26], brain [27], and liver [23], which is 
consistent with previous reports. We note that for typical carcinoid the most common site of 
metastasis, when metastasis occurs at all, was the liver and bone, also consistent with 
previous case reports [26], [28] and [29].
Tumors in the contralateral lung were observed in 11 of our patients with typical carcinoid. 
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia has been noted in both lungs 
[30], and the bilateral typical pulmonary carcinoids we observe may represent progression of 
diffuse idiopathic pulmonary neuroendocrine cell hyperplasia or carcinoid tumorlets. 
Patients with multiple typical bilateral pulmonary carcinoid tumors have been reported in 
the literature [31], [32], [33] and [34], have an excellent prognosis, and are managed with 
observation and resection of lesions that cause symptoms such as airway obstruction or 
hemoptysis.
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There are several limitations to our study, such as the number of patients included, the 
retrospective nature, and lack of long-term follow-up for all patients. The heterogeneity in 
patients and crossover to clinical trials makes it difficult to directly compare treatment 
regimens. We were also unable to evaluate the response by RECIST in 25 of 65 courses of 
treatment (39%). There was also no prospective approach to the use of diagnostic tests (5-
HIAA, chromogranin, PET-CT, and octreoscan) at our institution. Future studies may 
compare the sensitivity/specificity of the octreotide scan vs. PET-CT in evaluation of 
pulmonary carcinoid tumors, and whether pre-operative chromogranin or 5-HIAA levels 
may be prognostic in patients with resectable stage I-IIIA disease. The small number of 
patients receiving adjuvant treatment and the long duration of follow-up needed in this 
disease makes it difficult to draw conclusions on the impact this approach has in the survival 
of patients with resected disease.
In summary, these results support our previous finding that a subset of pulmonary carcinoid 
tumors are responsive to chemotherapy, with platinum + etoposide or temozolomide being 
the most frequently used effective regimens. The role of adjuvant systemic treatment for 
resected disease is an area of ongoing study. Larger studies will be necessary to compare the 
efficacy of treatment regimens to determine the optimal therapy for patients with metastatic 
disease.
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Fig. 1. 
(A) Time to recurrence for patients with atypical carcinoid tumors. Comparison of time to 
recurrence between atypical carcinoid patients (by stage) and typical carcinoid patients. p-
Value for comparison of recurrence between atypical carcinoid (any stage) and typical 
carcinoid (any stage) = <0.001 (Log-Rank). (B) Percentage alive of patients with atypical 
tumors by stage at initial presentation as measured from date of initial diagnosis.
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Fig. 2. 
Percentage survival for atypical carcinoid after development of metastatic disease. Ten of 27 
patients presented with metastatic disease.
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Table 1
Patient characteristics.
Atypical (n = 80) Typical (n = 220)
Median age at diagnosis (range) 61 years (21–82 years) 60 years (16–85 years)
Male 31 (39%) 64 (29%)
Stage at diagnosis
  IA 29 (36%) 148 (67%)
  IB 5 (6%) 19 (9%)
  IIA 12 (15%) 14 (6%)
  IIB 4 (5%) 10 (5%)
  IIIA 14 (18%) 13 (6%)
  IIIB 0 3 (1%)
  IV 16 (20%) 13 (6%)
Lymph node involvement
  N1 11 (14%) 11 (5%)
  N2 8 (10%) 14 (6%)
Location of tumora
  Left lower lobe 21 (24%) 55 (25%)
  Left upper lobe 11 (13%) 40 (18%)
  Right lower lobe 19 (22%) 51 (23%)
  Right middle lobe 24 (28%) 51 (23%)
  Right upper lobe 9 (10%) 43 (20%)
History of smoking 41 (48%) 91 (41%)
Reason for presentation (may overlap)
  Asymptomatic – detected on imaging 24 (28%) 96 (44%)
  Chest pain 7 (8%) 10 (5%)
  Cough 12 (14%) 23 (10%)
  Dyspnea 8 (10%) 8 (4%)
  Flushing 4 (5%) 0
  Hemoptysis 5 (6%) 12 (5%)
  Musculoskeletal pain (i.e. shoulder or back) 6 (7%) 5 (2%)
  Recurrent pneumonia 12 (14%) 26 (12%)
  Symptoms of metastatic disease (i.e. pathologic fracture, abdominal pain) 5 (6%) 0
  Upper respiratory tract infection 0 10 (5%)
  Wheezing/asthma symptoms 0 7 (3%)
aSome patients had tumors in multiple lobes; percentages reported for evaluable patients.
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Table 2
A. Disease course in patients undergoing resection.
Atypical Typical
Recurrent disease 26 (41%) 3 (1%)a
Risk of recurrence by initial stage, median years to recurrence (range)
  IA 7 of 29 (24%), 3.7 (0.9–32) 0
  IB 4 of 5 (80%), 4.8 (2.9–5) 0
  IIA 6 of 12 (50%), 3.5 (1–6.4) 0
  IIB 1 of 4 (25%), 0.4 0
  IIIA 8 of 14 (57%), 3.1 (1.2–11.6) 1 (33%, 8)
  IIIB N/A 0
B. Sites of metastasis noted on imaging for patients either at presentation or recurrence.
Atypical
(n = 34)
Typical
(n = 14)
Adrenal 2 (6%) –
Bone 18 (53%) 2 (14%)
Brain 6 (18%) –
Liver 27 (79%) 1 (7%)
Lung, contralateral 1 (3%) 11 (79%)a
Pancreas 2 (6%) –
Soft tissue 3 (9%) –
Spleen 2 (6%) –
a
Initial stage at diagnosis unavailable for 2 patients.
aCannot exclude synchronous or metachronous tumors.
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Table 3
Response to treatment for patients with pulmonary carcinoid.
Regimen Response
rate
Disease control
rate
Median PFS (months,
range)
Etoposide + platinum (n = 13) 23% 69% 7 (3–13)
Temozolomide-based (n = 14) 14% 57% 10 (6–29)
Other cytotoxic chemotherapy (n = 11)a 20% 70% 4 (3–18)
Any cytotoxic chemotherapy (n = 38) 18% 63% 7 (3–29)
  First-line cytotoxic chemotherapy (n = 20)b 20% 70% 8 (3–18)
  Second-line cytotoxic chemotherapy (n = 10) 20% 70% 5 (3–10)
  Third-line cytotoxic chemotherapy (n = 6) 16% 50% 5 (4–12)
Octreotide-based (n = 20)c 10% 70% 15 (6–72)
a11 regimens, 8 patients, including 1 patient treated with neoadjuvant cytotoxic chemotherapy.
b
Includes 4 patients treated with neoadjuvant cytotoxic chemotherapy.
c20 regimens, 15 patients.
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